Fundraising FoxAliada Therapeutics
Unicorn exit · $1.4Bacquired by AbbVieBoston, US · Founded 2021 · 2 known investors
Find your way into Aliada Therapeutics
Sign up to see every warm intro you have to Aliada Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aliada Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by AbbVie October 2024 · $1.4B ($1.4 billion) · source ↗
Aliada Therapeutics was a Boston-based clinical-stage biotech developing its MODEL platform to transport therapeutic antibodies across the blood-brain barrier for CNS diseases. Its lead candidate, an anti-amyloid-beta antibody, targeted Alzheimer's disease.
Founders & leadership
AJ
Adam J. RosenbergNamed on SEC filing
SE
Sari EpsteinNamed on SEC filing
LT
Laura TadvalkarNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$33M disclosed across 2 rounds · 2021–2022
▶$32MraisedDec 2022 · 5 investors · BiotechnologyRule 506(b)
▶$32MraisedDec 2022 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marian NakadaDirector
- Sari EpsteinExecutive Officer
- Laura TadvalkarDirector
- Adam J. RosenbergExecutive Officer, Director
- Jim SullivanDirector
- Joshua ResnickDirector
- Offering amount
- $32M
- Amount sold
- $32M
- Proceeds to insiders
- $1.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1MraisedJul 2021 · 2 investors · BiotechnologyRule 506(b)
▶$1MraisedJul 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam J. RosenbergExecutive Officer, Director
- Sari EpsteinExecutive Officer
- Laura TadvalkarDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Aliada Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Aliada Therapeutics do?
- Aliada Therapeutics was a Boston-based clinical-stage biotech developing its MODEL platform to transport therapeutic antibodies across the blood-brain barrier for CNS diseases. Its lead candidate, an anti-amyloid-beta antibody, targeted Alzheimer's disease.
- Who are Aliada Therapeutics's investors?
- Aliada Therapeutics's investors include RA Capital, Sanofi Ventures.
- How much funding has Aliada Therapeutics raised?
- Aliada Therapeutics has disclosed $33M raised across 2 rounds.
- Who acquired Aliada Therapeutics?
- Aliada Therapeutics was acquired by AbbVie.
- Where is Aliada Therapeutics headquartered?
- Aliada Therapeutics is headquartered in Boston, US.